DR. JOHN EFTHIMIOU APPOINTED CHIEF MEDICAL OFFICER
John Efthimiou BSc MD FRCP is a respiratory specialist physician/scientist trained in London and Oxford teaching hospitals, accredited in both Respiratory and General Medicine. He joined Thirty Group in June 2019 and has over 25 years’ experience in and advising large and small pharma and biotech companies, including GSK, Novartis, Roche/Chugai, Almirall, Vectura, Circassia, Glenmark, Protaffin.
John has contributed to the successful development (Phase I-IV) and commercialisation of many respiratory, infectious disease and dermatological medicines and has published over 90 scientific papers and patents.
30 TECHNOLOGY is developing and defining new models of care to treat many serious medical conditions by enhancing the body’s healing and defence mechanisms.
30 TECHNOLOGY Therapeutic Nitric Oxide